ArticleFrontiers in medicine2025
A study of three-time-point dynamic changes in aPS/PT and standard aPL antibodies and their association with IVF pregnancy outcomes in APS-related recurrent pregnancy loss.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate dynamic anti-phosphatidylserine/prothrombin (aPS/PT) and antiphospholipid (aPL) antibody changes in antiphospholipid syndrome-recurrent pregnancy loss (APS-RPL) patients and their relationship with pregnancy outcomes. Methods: This study included 100 RPL patients with APS features and 30 healthy women who had a normal delivery from 2020 to 2022. First, the differences in aPL and aPS/PT antibody levels between the study group and the control group were compared. Then, a mixed-design repeated measures analysis of variance (RM-ANOVA) was used to assess the time effects, group effects, and their interactions. Pairwise comparisons between time points within each group were performed using one-way repeated measures ANOVA. Finally, antibody levels at each time point were compared between the successful pregnancy group and the pregnancy loss group. Results: (1) The levels of aPS/PT immunoglobulin M (IgM) and anticardiolipin (aCL) IgG in the study group were significantly higher than those in the control group ( Conclusion: A post-treatment or early-pregnancy decline in aCL IgG, aPS/PT IgM, or aβ2GPI IgM is associated with successful pregnancy in APS-RPL patients, whereas early-pregnancy elevations in aPS/PT IgM and IgG are strongly linked to pregnancy loss. The distinct dynamic profiles of aPS/PT antibodies underscore their relevance to pregnancy outcomes, highlighting the value of longitudinal aPS/PT monitoring for identifying high-risk patients and informing individualized immunologic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.